← All organizations
Dompe Pharmaceuticals
Also known as: Dompé farmaceutici S.p.A. | DOMPE FARMACEUTICI | Dompé Farmaceutici | Dompé farmaceutici SpA | Dompé Farmaceutici S.p.A | Dompè farmaceutici SpA | Dompé s.p.a., Milan | Dompé SpA Milan | Dompé US | Domp Farmaceutici SpA
Highest phase reached
Phase 4
First clinical trial
May 1, 2005First marketed drug
Aug 22, 2018First NDA
Aug 22, 2018Last known activity
Apr 26, 2024
Timeline
1860s
- Jul 1, 1866
Dompe Pharmaceuticals— Founded
2010s
- Feb 28, 2012
Anabasis Srl— Acquired - Aug 22, 2018
cenegermin-bkbj— Marketing Organization
- Aug 22, 2018
cenegermin-bkbj— NDA Organization
Drugs by trial phase (13 distinct, 46 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (6 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Acute Pain
- Breast Neoplasms
- Bronchitis
- Capsule Opacification
- Cataract
- Corneal Ulcer
- Cough
- Delayed Graft Function
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Dry Eye Syndromes
- Edema
- Glaucoma
- Ischemia
- Keratitis
- Keratoconjunctivitis Sicca
- Kidney Diseases
- Macular Edema
- Pancreatitis
- Pancreatitis, Chronic
- Pemphigoid, Bullous
- Primary Graft Dysfunction
- Reperfusion Injury
- Retinitis
- Retinitis Pigmentosa
- Somatoform Disorders
- Triple Negative Breast Neoplasms
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT06411145Lead sponsorPhase 4Apr 26, 2024
- NCT06244316Lead sponsorPhase 2Jan 22, 2024
- NCT06244316OfficialPhase 2Jan 22, 2024
- NCT05835466CollaboratorPhase 2Jun 27, 2023
- NCT05496868Study directorPhase 2Jan 31, 2023
- NCT05496868Lead sponsorPhase 2Jan 31, 2023
- NCT05700864CollaboratorPhase 1Nov 1, 2022
- NCT05368402Lead sponsorPhase 2Jul 27, 2022
- NCT05212701Study directorPhase 2Apr 19, 2022
- NCT05212701Lead sponsorPhase 2Apr 19, 2022
- NCT05254990Study directorPhase 3Apr 6, 2022
- NCT05254990Lead sponsorPhase 3Apr 6, 2022
- NCT05136170Study directorPhase 3Dec 31, 2021
- NCT05136170Lead sponsorPhase 3Dec 31, 2021
- NCT05133180Lead sponsorPhase 3Nov 30, 2021
Details
- Founded
- Milan, IT Jul 1, 1866
- First NDA
- Aug 22, 2018
- Last known activity
- Apr 26, 2024
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy